FierceBiotech Apr 16, 2026 Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
FierceBiotech Apr 16, 2026 FDA advisory committee set to weigh taking action on certain unapproved peptides
FierceBiotech Apr 15, 2026 Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?
FierceBiotech Apr 15, 2026 Spain sets up Boston-focused VC fund with goal of raising $200M for biotechs
FierceBiotech Apr 15, 2026 Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
FierceBiotech Apr 15, 2026 Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS
FierceBiotech Apr 15, 2026 FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
FierceBiotech Apr 14, 2026 Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug
FierceBiotech Apr 14, 2026 Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
FierceBiotech Apr 14, 2026 Cell therapy biotech Obsidian leverages Galera reverse merger to go public
FierceBiotech Apr 14, 2026 Harbinger Health raises $100M for new suite of blood-based cancer detection tests
FierceBiotech Apr 14, 2026 Alamar Biosciences files for IPO amid opening life sciences funding window
FierceBiotech Apr 14, 2026 Boehringer, Amgen discard early immunology candidates over lack of clinical potential
FierceBiotech Apr 13, 2026 Kailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets